Table 1.
Detailed data of the included studies reporting the relationship of NLR, PLR, or CAR and prognosis after an esophageal cancer resection
| Authors | Year | Study period | Histology | NLR cut‐off | PLR cut‐off | CAR cut‐off | Outcome | Measures | Number | Age | Gender | Stage | Included patients were all performed curative resection | Adjuvant therapy | Median follow up month (range) | NOS |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ishibashi et al17 | 2018 | 2009‐2014 | All types | 3 | 135 | 0.085 | OS and CSS | NLR, PLR, CAR | 143 |
<65 = 29 ≥65 = 114 |
Female = 22 Male= 121 |
I = 33 II = 33 III = 60 IV = 17 |
Yes |
No = 71 Yes = 72 |
22.8 mo (0.6‐87.2 mo) |
7 |
| Hirahara et al3 | 2018 | 2006‐2014 | SCC | 1.6 | 147 | NA | OS | NLR, PLR | 147 |
<70 = 56 ≥70 = 91 |
Female = 15 Male= 132 |
I = 59 II = 33 III = 55 |
Yes | None | NR | 6 |
| Wang et al5 | 2017 | 2012‐2013 | SCC | 2 | 159 | NA | OS and DFS | NLR, PLR | 280 | 64.1 ± 7.4 |
Female = 47 Male = 233 |
0/I /II = 179 III /IV = 101 |
Yes |
No = 166 Yes = 114 |
NR | 6 |
| Gao et al6 | 2017 | 2005‐2015 | SCC | 2.86 | NA | NA | OS | NLR | 1281 |
NLR <2.86 = 58.1 ± 9.1 NLR ≥ 2.86 = 60.4 ± 31.17 |
Female = 276 Male = 1005 |
0 = 27 I = 125 II = 586 III = 520 IV = 23 |
No | NR | NR | 6 |
| Miyazaki et a.7 | 2016 | 2004‐2014 | All types | 3.49 | NA | NA | OS | NLR | 192 | 65.8 (42‐86) |
Female = 19 Male = 173 |
I = 58 II = 50 III = 60 IV = 24 |
Yes | None | 26.5 mo (1‐108 mo) | 7 |
| Geng et al11 | 2016 | 2002‐2012 | SCC | 1.7 | 120 | NA | OS | NLR, PLR | 916 |
<60 = 455 ≥60 = 461 |
Female = 220 Male = 696 |
0‐I = 168 II = 395 III = 353 |
Yes | None | 39 mo (3‐146 mo) | 6 |
| Wei et al13 | 2015 | 2006‐2010 | SCC | 1.835 | 163.8 | 0.095 | OS | NLR, PLR, CAR | 423 |
<54 = 146 ≥54 = 277 |
Female = 82 Male = 341 |
I = 54 II = 168 III = 142 IV = 59 |
No | NR | 35.7 mo (0.6‐95.6 mo) | 7 |
| Xu et al14 | 2015 | 2000‐2010 | SCC | 2.4 | 147 | 0.5 | OS | CAR, NLR, PLR | 468 |
<58 = 227 ≥58 = 241 |
Female = 52 Male = 416 |
I = 24 II = 181 III = 142 |
Yes |
No=272 Yes=196 |
49.9 mo (10.9‐88 mo) | 6 |
| Han et al16 | 2015 | 2007‐2008 | SCC | 2.6 | 244 | NA | OS and DFS | NLR, PLR | 218 |
<60 = 109 ≥60 = 109 |
Female = 41 Male = 177 |
I+II =133 III = 85 |
Yes |
No=136 Yes=82 |
38.6 mo (3‐71 months) | 6 |
| Feng et al15 | 2014 | 2005‐2008 | SCC | 3.5 | 150 | NA | OS | NLR and PLR | 483 |
<60 = 273 ≥60 = 210 |
Female = 72 Male = 411 |
NR | Yes | NR | NR | 6 |
Abbreviations: CAR, C‐reactive protein to albumin ratio; CSS, cancer‐specific survival; DFS, disease‐free survival; NA, not applicable; NLR, neutrophil to lymphocyte ratio; NOS, Newcastle‐Ottawa Quality Assessment Scale; OS, overall survival; PLR, platelet to lymphocyte ratio; SCC, squamous cell carcinoma.